Dublin, Dec. 16, 2016 -- Research and Markets has announced the addition of the "Global Travel Vaccines Market 2016-2020" report to their offering.
The global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020.
The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The report also includes a discussion of the key vendors operating in this market.
The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A.
R&D is budding due to a strong need for new efficacious and better tolerated vaccines. The market presents huge growth potential for vendors because of the growing incidence of infectious disease. This requirement is creating a demand for novel vaccines where major players are focusing their R&D efforts and once launched, should become the major growth drivers. Increased investment in R&D by major pharmaceutical companies would fuel the growth of the global travel vaccines market.
According to the report, the growing demand for vaccines among international travelers is one of the major factors driving the market growth. Many international and national bodies have mandated that the immigrants should be vaccinated before traveling to disease-prone areas. Considering vaccines are largely perceived as a prevention mechanism against the spread of any infectious disease; it is making a specific requirement in international traveler's list.
Further, the report states that vaccines are temperature sensitive in nature and hence, need to be kept under adequately controlled temperature throughout their supply chain. To avoid any loss of potency during its distribution, vaccines need to be kept in 'vaccine cold chain', which includes refrigerators or freezers. Inadequately stored vaccines lose their efficacy to protect against diseases and can lead to increased local reactions.
Key vendors
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi
Other prominent vendors
- Abbott
- AstraZeneca
- Bavarian Nordic
- Baxter
- Beijing Minhai Biotechnology
- Bharat Biotech
- Bharat Immunologicals and Biologicals
- Bio-Med
- Seqirus CSL
- Crucell
- CSL
- Dynavax Technologies
- Emergent BioSolutions
- GlycoVaxyn
- GreenSignal Bio Pharma
- Hualan Biological Engineering
- Imunoloski Zavod
- Indian Immunologicals
- Janssen Pharmaceuticals
- LG Life Sciences
- Lupin
- Mitsubishi Tanabe Pharma
- Novavax
- Nuron Biotech
- Panacea Biotec
- Pfizer
- Protein Sciences
- Roche
- SK Chemicals
- Sinovac Biotech
- Takeda Pharmaceutical
- Vacunas Finlay
- Valeant Pharmaceuticals
- Valneva,
- Zydus Cadila
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Regulatory scenario of vaccines
Part 06: Market landscape
Part 07: Market segmentation by disease type
Part 08: Market segmentation by composition
Part 09: Geographical segmentation
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/9znd7k/global_travel
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Travel and Tourism, Vaccines


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 



